Stiris Research Inc. Awarded Phase IIa Amyotrophic Lateral Sclerosis Study

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, announces the award of a Phase IIa Amyotrophic Lateral Sclerosis (ALS) study.

“We are very excited to begin work on a new study for individuals living with ALS. There is an urgent need for new treatments for ALS and we are glad that we can be a part of bringing this potential new treatment into the clinical trial setting herein Canada.” said Shantal Feltham, President & CEO.

​Amyotrophic lateral sclerosis (ALS), is a rare neurological disease that affects motor neurons—those nerve cells in the brain and spinal cord that control voluntary muscle movement. Voluntary muscles are those we choose to move to produce movements like chewing, walking, and talking. Nearly all cases of ALS are considered sporadic. This means the disease seems to occur at random with no clearly associated risk factors and no family history of the disease. Although family members of people with sporadic ALS are at an increased risk for the disease, the overall risk is very low and most will not develop ALS.

(https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als#:~:text=Amyotrophic%20lateral%20sclerosis%20(ALS)%2C,chewing%2C%20walking%2C%20and%20talking.)